LD-2 disclosure · 4th Quarter - Report
CARIS SCIENCE INC
Client
- Description
- Providing precision medicine services to patients battling aggressive cancers.
- Location
- Texas · United States of America
Registrant
- Description
- Health care consulting
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesMedicare/Medicaid
Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act; HR 2617 Consolidated Appropriations Act of 2023
LobbyistsAMY JENSEN
Covered position (AMY JENSEN): Special Assistant to the President for Legislative Affairs; Assistant to the Speaker for Policy; Legislative Assistant; Policy Analyst
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medical/Disease Research/Clinical Labs
Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. White House Cancer Moonshot Initiative; HR 2617 Consolidated Appropriations Act of 2023
LobbyistsAMY JENSEN
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
The Valid Act and appropriate regulatory structure for advanced molecular and genomic testing, HR 2617 Consolidated Appropriations Act of 2023
LobbyistsAMY JENSEN